Oorsprong van het eerstegraads netwerk van Vicky Gwosdz
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
Galapagos Genomics NV
Galapagos Genomics NV Pharmaceuticals: MajorHealth Technology Galapagos is a discovery company focused on the identification of disease modifying drug targets by functionally screening human disease models and the subsequent progression of these targets into drug discovery. Galapagos is a genomics based drug discovery company with programs in osteoporosis, rheumatoid arthritis, osteoarthritis, Alzheimer's disease and asthma.
5
| Extinct | Pharmaceuticals: Major | 5 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Vicky Gwosdz via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
ASTRAZENECA PLC | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
ALGORAE PHARMACEUTICALS LIMITED | Pharmaceuticals: Other | Chief Executive Officer | |
GALAPAGOS NV | Biotechnology | Founder Chief Tech/Sci/R&D Officer | |
Johnson & Johnson Innovation - JJDC, Inc.
Johnson & Johnson Innovation - JJDC, Inc. Investment ManagersFinance Johnson & Johnson Innovation JJDC Inc (Johnson & Johnson Innovation JJDC) is a venture capital subsidiary of Johnson & Johnson founded in 1973. The firm is headquartered in New Brunswick, New Jersey. | Investment Managers | Corporate Officer/Principal | |
Galapagos Biotech Ltd.
Galapagos Biotech Ltd. BiotechnologyHealth Technology Galapagos Biotech Ltd. operates as a drug discovery company which provides discovery technologies and services. Its technologies include Chemogenomics and Silico. The company was founded by Kenneth Leslie Powell and Janet Maureen Thornton in July 8, 1997 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Director/Board Member | |
University of Cambridge | College/University | Doctorate Degree | |
Dr. Reddy's Research & Development BV
Dr. Reddy's Research & Development BV Pharmaceuticals: MajorHealth Technology Dr. Reddy's Research & Development BV is engaged in the development and manufacture of injectable pharmaceutical products. It provides formulation, development, drug delivery, and clinical material manufacturing services to biotech and pharmaceutical companies worldwide. The company was founded by Joost J. M. Holthuis on July 20, 1995 and is headquartered in Leiden, Netherlands. | Pharmaceuticals: Major | Chairman | |
Mogen International Nv
Mogen International Nv Pharmaceuticals: OtherHealth Technology Part of AstraZeneca PLC, Mogen International Nv is a Dutch company that specializes in medicinal chemicals and botanical products. The company is based in Leiden, the Netherlands. Mogen International was acquired by Zeneca Group Plc on May 01, 1997 for $74.96 million. | Pharmaceuticals: Other | Corporate Officer/Principal | |
Molecular Probes, Inc.
Molecular Probes, Inc. BiotechnologyHealth Technology Molecular Probes, Inc. has manufactured fluorescence-based detection solutions for use in labeling molecules for biological research and drug discovery. The company was headquartered in Eugeme, OR. | Biotechnology | Corporate Officer/Principal | |
Zeneca Garden Care
Zeneca Garden Care Pharmaceuticals: OtherHealth Technology Part of AstraZeneca PLC, Zeneca Garden Care is a British company that develops and manufactures pharmaceutical products, agrochemicals, and specialty chemicals. The company is based in Macclesfield, UK. Zeneca Garden Care was acquired by Zeneca Group Plc on January 01, 1995 for $84.16 million. | Pharmaceuticals: Other | Chief Tech/Sci/R&D Officer | |
MITHRA PHARMACEUTICALS S.A. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
CELLECTIS S.A. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Katholieke Universiteit Leuven | College/University | Doctorate Degree | |
Swansea University | College/University | Doctorate Degree | |
OXURION NV | Pharmaceuticals: Major | Chairman | |
Vlaams Instituut voor Biotechnologie - Flanders Institute
Vlaams Instituut voor Biotechnologie - Flanders Institute Other Consumer ServicesConsumer Services Vlaams Instituut voor Biotechnologie - Flanders Institute operates as a non-profit organization, provides research and development services. It specializes in translating basic scientific results into pharmaceutical, agricultural and industrial applications. The company was founded on January 1, 1996 and is headquartered in Ghent, Belgium. | College/University | Director/Board Member | |
Intrexon ActoBiotics NV
Intrexon ActoBiotics NV BiotechnologyHealth Technology Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium. | Biotechnology | Chairman | |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Janssen Pharmaceutica NV
Janssen Pharmaceutica NV Pharmaceuticals: MajorHealth Technology Janssen Pharmaceutica NV engages in the development of medical solutions. It offers research and development services in the field of mental illness, neurological disorders, anesthesia, analgesia, gastrointestinal disorders, fungal infection, allergies and cancer. The firms products include Zytiga, Caelyx, Dacogen, Edurant, Fentanyl-Janssen, Intelence, Leustatin, , Pariet, and Reminyl. The company was founded in 1953 by Paul Janssen and is headquartered in Beerse, Belgium. | Pharmaceuticals: Major | Chief Executive Officer | |
The Janssen Research Foundation | President | ||
InteRNA Technologies BV
InteRNA Technologies BV BiotechnologyHealth Technology InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands. | Biotechnology | Director/Board Member | |
FlandersBio vzw
FlandersBio vzw Miscellaneous Commercial ServicesCommercial Services FlandersBio vzw is a life sciences cluster organization based in Flanders, Belgium. FlandersBio creates value by organizing networking and training activities, supporting internationalization, providing services, and building expertise. The Belgian company was founded by Jean Marie Stassen. | Miscellaneous Commercial Services | Chairman | |
Biocartis SA
Biocartis SA Medical SpecialtiesHealth Technology Biocartis SA develops molecular diagnostic solutions. It focuses on Oncology. The firm’s products include Idylla and Oncology assays and mutation tests. It also provides instant access to personalized medicine for patients. The company was founded by Rudi Pauwels in 2007 and is headquartered in Lausanne, Switzerland. | Medical Specialties | Director/Board Member | |
Wageningen University | College/University | Graduate Degree | |
Het Vlaams Parlement | Corporate Officer/Principal | ||
Viziphar Biosciences BV | Chief Executive Officer | ||
Vivactis NV | Miscellaneous | Director/Board Member | |
DCPrime BV
DCPrime BV Pharmaceuticals: MajorHealth Technology DCPrime BV engages in the provision of therapeutic vaccines for the treatment of cancer. It develops whole-cell-based vaccine addressing blood cancers with a high risk of relapse. The company was founded by Ada M. Kruisbeek and Rik J. Scheper in March 2005 and is headquartered in Leiden, the Netherlands. | Pharmaceuticals: Major | Director/Board Member | |
Molecular Probes Europe BV | Corporate Officer/Principal | ||
Netherlands Foreign Investment Agency
Netherlands Foreign Investment Agency Financial ConglomeratesFinance Netherlands Foreign Investment Agency provides business investment services. The private company is based in the Netherlands and has no subsidiaries mentioned in the provided metadata. | Financial Conglomerates | Corporate Officer/Principal | |
University of Antwerp | College/University | Doctorate Degree Graduate Degree | |
Neem Biotech Ltd.
Neem Biotech Ltd. Pharmaceuticals: MajorHealth Technology Part of InQpharm Group, Neem Biotech Ltd. is a British biotech company focused on developing groundbreaking ways of defeating big health challenges. The company is based in St. Mellons, UK. Leveraging their unique position in antimicrobial R&D, they have expertise in drug discovery. Neem Biotech was acquired by InQpharm Group on August 09, 2012. | Pharmaceuticals: Major | Chief Executive Officer | |
Diatranz Otsuka Ltd.
Diatranz Otsuka Ltd. Pharmaceuticals: MajorHealth Technology Diatranz Otsuka Ltd. manufactures pharmaceutical products. Its product, DIABECELL, is used to treat type1 diabetes. The company was founded on November 11, 2011 and is headquartered in Auckland, New Zealand. | Pharmaceuticals: Major | Chief Executive Officer | |
BIOCARTIS GROUP NV | Medical Specialties | Director/Board Member | |
DoseVue NV
DoseVue NV Medical SpecialtiesHealth Technology DoseVue NV is developing innovative technologies for convenient and accurate in-vivo dosimetry. It offers DoseWire Series 100 & DoseWire Series 200. The company was founded by Emiliano D Agostino in March 2013 and is headquartered in Turnhout, Belgium. | Medical Specialties | Chairman | |
Institute For Human Organ & Disease Model Technologies | Director/Board Member | ||
HepaRegeniX GmbH
HepaRegeniX GmbH Miscellaneous Commercial ServicesCommercial Services HepaRegeniX GmbH engages in the development of treatment for acute and chronic liver diseases. It focuses on Mitogen-Activated Protein Kinase 4, which unlocks the regenerative capacity of hepatocytes even in severely diseased livers. The company was founded in by Wolfgang Albrecht in 2017 and is headquartered in Tuebingen, Germany. | Miscellaneous Commercial Services | Chairman | |
Zaluvida Holdings Pte Ltd.
Zaluvida Holdings Pte Ltd. Other Consumer ServicesConsumer Services Zaluvida Holdings Pte Ltd. provides solutions that improve the lives of livestock and protect the planet. Zaluvida Holdings is based in Singapore, Singapore. The Singaporean company also offers products that help pets stay healthier. The private company's focus is on developing new alternatives to antibiotics that can benefit farmers. and has subsidiaries in Switzerland, Germany, and Malaysia. | Other Consumer Services | Chief Tech/Sci/R&D Officer | |
Enzyre BV
Enzyre BV Packaged SoftwareTechnology Services Enzyre BV develops biochip platform that enzymatic reactions can be measured. The company is headquartered in Nijmegen, the Netherlands. | Packaged Software | Chief Executive Officer | |
Apaxen SA
Apaxen SA BiotechnologyHealth Technology Apaxen SA is a privately-held biotechnology company that was founded in 2018 and is based in an undisclosed location. The Belgian company has raised €5.4 million in equity and grant funding since its A round in 2019. Apaxen is focused on developing a pipeline of NLRP3 inflammasome inhibitors with a novel mechanism of action for the treatment of chronic inflammatory and autoimmune diseases. The company's clinical candidate, MFC-1040, is an orally bioavailable and selective small molecule NLRP3 inflammasome inhibitor that has demonstrated efficacy in multiple animal models of chronic inflammatory disease and pulmonary fibrosis. The company's team combines the experience required for clinical development of its products and is supported by a world-class team of scientific advisors. Apaxen has a pipeline of products at discovery and preclinical stages of development for the treatment of diseases associated with chronic inflammation that depend on NLRP3 inflammasome activation. The company was founded in 2018 by Gael Jalce, Enrico Jose Adolfo Bastianelli, and Bart Wuurman has been the CEO of the company since 2020. | Biotechnology | Chairman | |
Cergentis BV
Cergentis BV Miscellaneous Commercial ServicesCommercial Services Part of Solvias AG, Cergentis BV is a Dutch genomics company that develops and commercializes TLA-based diagnostic kits for targeted complete next-generation sequencing of (trans) genes and gene editing events. The company is based in Utrecht, Netherlands. The company also provides commercial services for leading research institutes and pharmaceutical companies worldwide. The company was founded in 2012. Joris Schuurmans has been the CEO of the company since 2020. Cergentis was acquired by Solvias AG on July 12, 2022. | Miscellaneous Commercial Services | Director/Board Member | |
Leyden Laboratories B.V.
Leyden Laboratories B.V. Miscellaneous Commercial ServicesCommercial Services Leyden Laboratories B.V. is a biotechnology company based in Amsterdam, Netherlands. Leyden Labs aims to protect humanity from known and future viruses by targeting commonalities of viral families. The Dutch company has developed a portfolio of accessible intranasal product candidates that may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The company's energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. Leyden Labs is backed with $200m by blue-chip investors Casdin Capital, GV (formerly Google Ventures), F-Prime Capital, Byers Capital/Brook Byers, SoftBank Investment Advisers, Invus, and Bluebird Ventures. The company was founded in June 2020 by Koenraad Wiedhaup, Jaap Goudsmit, Domenico Valerio, and Ronald H. P. Brus, with Koenraad Wiedhaup serving as the CEO since incorporation. | Miscellaneous Commercial Services | Director/Board Member |
Statistieken
Internationaal
België | 21 |
Nederland | 12 |
Verenigd Koninkrijk | 8 |
Verenigde Staten | 5 |
Nieuw-Zeeland | 3 |
Sectoraal
Health Technology | 29 |
Consumer Services | 8 |
Commercial Services | 6 |
Finance | 4 |
Miscellaneous | 2 |
Operationeel
Director/Board Member | 20 |
Corporate Officer/Principal | 13 |
Chief Tech/Sci/R&D Officer | 10 |
Chairman | 10 |
Chief Executive Officer | 9 |
Sterkste connecties
Insiders | |
---|---|
Staf van Reet | 22 |
Graham Dixon | 18 |
Onno van de Stolpe | 13 |
Dirk Pollet | 6 |
Andrea Grant | 4 |
- Beurs
- Insiders
- Vicky Gwosdz
- Bedrijfsconnecties